RxDoctor Payments Data

Nancy Pajaro, MD

Family Medicine · Birmingham, ALNPI 1083713754

Payments from drug & device makers

$832in general payments, 2019–2025

Across 44 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$269
  • AstraZeneca$117
  • Lilly USA, LLC$90
  • Amgen$70
  • Kowa Pharmaceuticals America, Inc.$45
  • Phathom Pharmaceuticals, Inc.$45
  • plus $198 from 8 others

What the payments were for

  • Food & beverage$832100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$832 in reported general payments places this provider in the 50th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$28,471
Medicare patients
40
Services billed
451

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide147$195,625
EliquisApixaban52$58,552
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$37,957
JardianceEmpagliflozin32$35,567
FarxigaDapagliflozin Propanediol26$28,125
LinzessLinaclotide28$27,490
MyrbetriqMirabegron20$19,836
MounjaroTirzepatide17$18,153
TradjentaLinagliptin15$15,545
Breo ElliptaFluticasone/Vilanterol12$9,942
Repatha SureclickEvolocumab11$6,996
VeozahFezolinetant13$6,736
FetzimaLevomilnacipran Hcl13$6,354
Sucralfate32$5,860
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$4,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$269$195,625147 claims
AbbVieLinzess, Fetzima$24$33,84441 claims
AstraZenecaFarxiga$117$28,12526 claims
Astellas Pharma US IncMyrbetriq, Veozah$21$26,57233 claims
Lilly USA, LLCMounjaro, Humulin 70-30$90$21,07029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →